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Summary: Advanced glycation end products were determined immunologically in blood from diabetics, patients
with renal failure and subjects with various other diseases. Elevation of advanced glycation end products levels in
serum is not confined to the diabetic state but was also observed in some severely ill subjects. Patients with end-
stage renal disease on dialysis displayed high advanced glycation end products levels in serum, irrespective of the
presence or absence of diabetes. In contrast, advanced glycation end products levels in uraemic subjects not treated
by dialysis were not different from controls. In diabetics, levels of advanced glycation end products were related to
the state of late complications. Diabetics without sequelae showed advanced glycation end products within the
normal range, whereas in the presence of late complications mean advanced glycation end products levels were
elevated. In the case of retinopathy the increase in advanced glycation end products was associated with the severity
of retinal status.
Introduction
Prolonged exposure to high glucose levels is thought to
be an important factor for the development of diabetic
late complications. One possible mechanism, contribut-
ing to diabetic sequelae, might be the increased forma-
tion of advanced glycation end products during hyper-
glycaemia. In the first step of this reaction, reducing
sugars such as glucose are covalently attached to free
amino groups of proteins to form labile Schiff bases
which subsequently undergo Amadori rearrangement to
stable ketoamines. Formation of Amadori products is
well established for a number of proteins and has been
found to be increased in diabetes (for a review see 1. c.
(1)). The Amadori product undergoes very slowly a
series of rearrangement reactions leading to a large
number of different compounds, called advanced glyca-
tion end products and abbreviated as AGE (2). Ad-
vanced glycation end products may be implicated in the
development of diabetic late complications either by
their direct chemical reactivity, e. g. crosslink formation
(3), trapping of plasma proteins (4), generation of free
radicals (5) or inactivation of nitric oxide (6), or by their
indirect actions such as stimulation of cytokine forma-
tion (7) or enhancing synthesis of extracellular matrix
components or cell proliferation (8), respectively (for a
review see (9)).
!) Funding organisation: Deutsche Forschungsgemeinschaft, Bad
Godesberg, Germany
The nature of advanced glycation end products is still
unknown. Some discrete products such as pyrraline (5-
hydroxy-methyl-1 -alkylpyrrole 2-carbaldehyde) (10),
pentosidine (imidazo(4,5-Z?)pyridinium) (11) and 3-
deoxyfructose and 3-deoxyglucosone (12) have been
found to represent advanced glycation end products
formed in vivo and to be present in human serum pro-
teins and tissues. Furthermore, advanced glycation end
products have been detected in high and low molecular
forms in human serum, surprisingly showing their high-
est levels in subjects suffering from end-stage renal dis-
ease (13-16).
Until recently, measurement of advanced glycation end
products was impeded by the lack of specific and sensi-
tive assays. Some advanced glycation end products ex-
hibit fluorescence at 440 nm upon excitation at 370 nm
(17), however, fluorescence can also result from the re-
action between lipid peroxidation products and proteins
(18) or from the oxidation of amino acids by free radi-
cals (19, 20). Measurement of specific advanced glyca-
tion end products like pentosidine, may underestimate
the quantities of advanced glycation end products in tis-
sues and serum. In this study advanced glycation end
products were determined immunologically with an anti-
advanced glycation end products antibody which recog-
nizes epitope(s) common to a large number of different
advanced glycation end products (16, 21, 22). Measure-
ment was performed in blood from apparently healthy
subjects, diabetics, patients with renal diseases and from
non-diabetic, non-uraemic patients. Evidence is pre-
sented that the levels of advanced glycation end pro-
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ducts in serum are related to diabetic late complications
rather than to kidney failure, and furthermore that dialy-
sis per se might lead to an enhancement of advanced
glycation end products.
Materials and Methods
Serum or heparin plasma was obtained from 25 normal healthy
persons (22-60 years old), from 31 non-diabetic patients with end-
stage renal disease (33-87 years old; 19 on haemodialysis and
five on continuous ambulatory peritoneal dialysis), from 12 non-
diabetic, non-uraemic patients with various diseases (18-88 years)
and from 85 diabetic patients (16-93 years of age). Twenty-nine
of the diabetics suffered from end-stage renal disease, 18 were
treated with haemodialysis and three with continuous ambulatory
peritoneal dialysis. Duration of diabetes ranged from newly discov-
ered to 40 years. Of the diabetics without end-stage renal disease
24 were treated with insulin, 16 with oral antidiabetics, 9 with
insulin in combination with oral antidiabetics and 7 with diet alone.
Advanced glycation end products were detected immunochemi-
cally in a competitive ELISA using an antibody prepared by our
group according to Nakayama et al. (21). Characterization of the
anti-advanced glycation end products antibody and performance of
the assay have been described in detail previously (16, 22). Briefly,
advanced glycation end products human albumin was prepared in
vitro by incubating 43.3 μπιοΐ/ΐ albumin for 34 days at 37 °C with
55.5 mmol/1 glucose at pH 9.5. For performance of the assay one-
half of a microtitre plate (Nunc immunoplates) was coated by add-
ing 0.1 ml advanced glycation end products human albumin, 0.5
mg/1, in 0.1 mol/1 carbonate buffer, pH 9.6, while the second half
was coated with human albumin incubated in the absence of glu-
cose, these wells serving for the blank values. After incubation
overnight at 4 °C, wells were washed with 154 mmol/1 NaCl con-
taining 0.5 ml/1 Tween 20, then blocked with 5 g/1 bovine serum
albumin in phosphate-buffered saline, pH 7.4. Thereafter 0.05 ml
of the 1 : 4 diluted samples and 0.05 ml of 1 :1000 diluted rabbit
antiserum were added to the wells. Plates were incubated for l h
at room temperature and overnight at 4 °C. Then wells were
washed again and developed with a peroxidase-conjugated anti-
rabbit IgG from sheep, using o-phenylenediamine as substrate. Im-
munoreactivity of samples was expressed as equivalents per litre
(eq/1), one eq/1 corresponding to the amount of antibody-reactive
material found in advanced glycation end products human albumin
at a protein concentration of 1 mg/1. The intra-assay coefficient of
variation was 7.1% (mean value =118 eq/1, n = 16), while the
inter-assay coefficient of variation was 8.2% (mean value = 26
eq/1, n = 37). The same values for advanced giycation end products
were obtained for serum and for lithium heparinate plasma (16).
Serum fructosamine was assayed with a test kit from Boehringer,
Mannheim, Germany, according to the supplier's instructions, and
results were expressed on the basis of the serum protein content.
Creatinine was determined by the Jaffe, and serum protein by the
biuret reaction on a Hitachi 717 multichannel analyser (Boehringer,
Mannheim, Germany).
Statistical evaluation was performed according to the instructions
of Sachs (23). Statistical significance was calculated by the U-test
of Mann-Whitney and Wilcoxon. Significance was taken as
p < 0.05. Results are given as mean values ± SD.
Results
Results of advanced glycation end products measurement
in serum are given in table 1. In apparently healthy per-
sons serum advanced glycation end products concentra-
tions ranged from 25 to 50 eq/1. From these data a refer-
ence range of 21-49 eq/1 was calculated (mean value
± 2 SD). No relationship existed betweerj serum ad-
vanced glycation end products values and age in normal
controls. As serum levels of advanced glycation end pro-
ducts are thought to be dependent on renal elimination, di-
abetic patients are presented in groups according to the se-
verity of their renal impairment. Apparently, serum ad-
vanced glycation end products values increase with
decreasing kidney function, the highest values being dis^
played by diabetics with end-stage renal disease on
haemodialysis or continuous ambulatory peritoneal dialy-
sis. No significant difference in advanced glycation end
products content was observed between diabetic and non-
diabetic patients requiring haemodialysis or continuous
ambulatory peritoneal dialysis. Surprisingly, advanced
glycation end products values in sera from non-diabetics
with end-stage renal failure not treated by dialysis are not
different from normal controls. Diabetic and non-diabetic
subjects treated with continuous ambulatory peritoneal
dialysis showed considerably higher advanced glycation
end products concentrations than subjects treated by
haemodialysis (84 ± 23.2 eq/1, n = 8 and 64 ± 25.4 eq/1,
n = 37, p < 0.05), respectively. No correlation existed in
diabetic and uraemic patients between serum advanced
glycation end products and creatinine.
In order to get more insight into the mechanism leading
to the elevation of serum advanced glycation end pro-
ducts in non-diabetic uraemics on haemodialysis or con-
tinuous ambulatory peritoneal dialysis, the serum
fructosamine content was determined. Assuming that
glucose-containing dialysis fluids may favour advanced
glycation end products formation, one might expect that
serum protein glycation would be increased too. In the
group of non-diabetic uraemics without dialysis one out
of seven patients (14.3%) displayed a slightly elevated
fructosamine level, while in non-diabetic uraemics un-
dergoing dialysis 9 out of 19 subjects (47.4%) had
increased fructosamine values. The difference between
the two groups, however, is not statistically significant
(271 ±28.4 μπιοΐ/ΐ, n = 7 and 289 ±47.1 μπιοΐ/ΐ,
η = 19). In uraemic patients without dialysis no correla-
tion existed between advanced glycation end products
and fructosamine levels (r = -0.064), whereas a weak
but statistically significant relationship was observed be-
tween advanced glycation end products and fructosam-
ine in non-diabetic subjects on dialysis (r = 0.436,
ρ < 0.05) (fig. 1).
In non-diabetic, non-uraemic patients with various other
diseases no statistically significant differejice in serum
advanced glycation end products content was observed
as compared to normal controls. Details of these latter
patients are presented in table 2. As may be seen, three
out of 12 patients displayed elevated serum advanced
glycation end products values. This increase occurred in
severly ill patients whose blood; samples were drawn
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Tab. 1 Advanced glycation end products concentrations in sera from normal controls, diabetics,
patients with end-stage renal failure and with other diseases.
n Serum advanced glycation end products (eq/1) Serum creatinine (μηιοΐ/ΐ)
Mean value SD
Normal controls
Diabetics without renal failure
Diabetics with moderate renal failure
Uraemic diabetics
Uraemic diabetics on
haemodialysis or continuous
ambulatory peritoneal dialysis
Uraemic non-diabetics
Uraemic non-diabetics on
haemodialysis or continuous
ambulatory peritoneal dialysis
Patients with various diseases
25
32
24
8
21
7
24
12
35
40
47
53
66
33
69
41
7.1
14
24.7
23.5
25.2
14.6
27.1
20.2
Range
25- 50
17- 74
20-129
22- 87
28-120
21- 64
34-113
17- 87
Pa
n.s.
n.s.
n.s.
<0.0005
n.s.
<0.0005
n.s.
Mean value SD
80
83
186
522
611
540
788
115
8.8
16.8
84
133
154
204
191
58
Range
71- 97
62- 124
80- 425
292- 690
310- 903
301- 876
416-1336
53- 283
Compared with controls
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Fig. 1 Correlation between serum advanced glycation end pro-
ducts and fructosamine concentrations in non-diabetic uraemics
without dialysis (a) and in non-diabetic uraemics treated with
haemodialysis (o) or continuous ambulatory peritoneal dialysis
W 0>).
Tab. 2 Advanced glycation end products concentrations in patients suffering from diseases not related
to diabetes mellitus or renal failure.
Case
1
2
3
4
5
6
7
8
9
10
11
12
Clinical diagnosis
Cerebral cramps
Coronary heart disease, cardiac insufficiency
Coronary heart disease, stroke
Cirrhosis of the liver disseminated
intravascular coagulation, exitus
Infarction of cerebellum
Cirrhosis of the liver
E. coli sepsis, exitus
Acute pulmonary embolism, exitus
Intoxication by ethanol
M. Waldenstr m, exitus
Coronary heart disease, cardiac insufficiency
Ventricular fibrillation, exitus
Age
(years)
64
66
68
55
76
48
70
79
18
67
88
81
Serum creatinine
(μπιοΐ/ΐ)
80
97
88
142
97
124
283
97
53
106
88
124
Urinary protein
(+)
negative
negative
negative
negative
n.d.*
n.d.*
n.d.*
n.d.*
negative
negative
negative
Advanced glycation
end products (eq/1)
23
47
17
39
31
27
87
51
29
33
39
70
Not determined
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Tab. 3 Serum advanced glycation end products concentrations as related to diabetic late complications.
n Serum advanced glycation end products (eq/1)
Compared with controls
Mean value SD Range P*
Normal controls
Diabetics without late complications
Diabetics with retinopathy
Diabetics with nephropathy
Diabetics with peripheral macroangiopathy
Diabetics with cerebral macroangiopathy
Diabetics with coronary heart disease
Diabetics with neuropathy
25
18
20
32
12
7
19
12
35
35
53
48
56
53
46
53
7.1
7.2
24.3
24.1
28.1
24.8
21.6
26.2
25- 50
25- 52
22-.129
20-129
24-129
20- 87
17- 87
24-129
n.s.
<0.0025
<0.05
<0.0025
n.s.
n.s.
<0.0025
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Fig. 2 Levels of serum advanced glycation end products related
to diabetic sequelae.
Patient groups:
1, Normal controls;
2, diabetics without late complications;
3, diabetics with retinopathy;
4, diabetics with nephropathy (moderate renal failure and uraemics
without haemodialysis or continuous ambulatory peritoneal di-
alysis);
5, diabetics with peripheral macroangiopathy;
6, diabetics with cerebral macroangiopathy;
7, diabetics with coronary heart disease;
8, diabetics with neuropathy.
The horizontal lines indicate the lower and upper limit of the refer-
ence range (21 -49 eq/1).
shortly before death. In patients with diseases not related
to diabetes or renal failure, a significant (p < 0.01) rela-
tionship between advanced glycation end products and
creatinine was discernible (r = 0.767).
In order to determine whether serum advanced glycation
end products levels might be associated with the occur-
rence of diabetic late complications, correlations were
sought between advanced glycation end products values
and the presence of diabetic sequelae. Results are given
in table 3 and figure 2. As may be clearly seen, advanced
glycation end products values in diabetics without late
complications are not different from results found in
normal controls. In contrast, advanced glycation end
products mean values are increased in the presence of
sequelae. A highly significant difference versus controls
was found in patients with retinopathy, peripheral
macroangiopathy and with polyneuropathy, while the
advanced glycation end products concentration in pa-
tients suffering from cerebral macroangiopathy and cor-
onary heart disease was not different from normal con-
trols. It should be mentioned, however, that in the pres-
ence of sequelae, advanced glycation end products
levels could be normal or even slightly decreased, the
latter occurring mainly in patients with nephropathy. In
the case of retinopathy and nephropathy, the advanced
glycation end products content was related to the sever-
ity of retinal and renal status; results are given in table
4. The mean value of advanced glycation end products
in background retinopathy amounted to 37 ± 11.6 eq/1,
and did not differ from the values observed in diabetics
without late complications, whereas in proliferative reti-
nopathy, values of 61 ± 28,9 eq/1 were observed. In con^
trast, in nephropathy advanced glycation end products
levels and albumin ri are not interrelated. Advanced
glycation end products concentrations in normo-albu-
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Tab. 4 Relationship between serum advanced glycation end products concentrations and severity of
diabetic retinopathy and nephropathy.
Diabetics without late complications
Diabetics with
background retinopathy
proliferative retinopathy
Diabetics with
normoalbuminuria
microalbuminuria
gross proteinuria
n
18
7
9
8
7
21
Serum advanced glycation end products (eq/1)
Mean value
35
37
61
42
36
44
SD
7.2
11.6
28.9
15.1
11.8
25
Range
25- 52
22- 50
29-129
25- 72
21- 58
20-129
P*
n.s.
<0.005
n.s.
n.s.
n.s.
* Compared with diabetics without late complications
minuria (albumin < 30 mg/g creatinine), microalbumin-
uria (30-300 mg/g creatinine), and in gross proteinuria
(> 300 mg/g creatinine) were 42 ± 15.1 eq/1, 36 ± 11.8
eq/1 and 44 ± 25 eq/1, respectively. It is noteworthy that
advanced glycation end products levels are not related
to the total number of late complications exhibited by
any one patient.
Discussion
Occurrence of advanced glycation end products in se-
rum and their increase in diabetics and patients with end-
stage renal disease is how well established (13 —16, 24—
28). From these studies, it is reasonable to assume that
elevation of serum advanced glycation end products
may be caused by increased formation during hypergly-
caemia and uraemia or by decreased elimination due to
renal failure or ineffective dialysis procedures. However,
our results raise certain questions as to the cause of the
elevation of serum advanced glycation end products in
patients with kidney disease. Although the values for
advanced glycation end products in diabetics tended to
increase with impairment of kidney function, no correla-
tion existed between advanced glycation end products
levels and serum creatinine or albuminuria. Further, in
contrast to Papanastasiou et al. (26), we found no
increase in advanced glycation end products values in
non-diabetic patients with end-stage renal disease, not
yet dialysed, but hospitalised for receiving their first di-
alysis session, whereas dialysed subjects displayed high
values. From this result, one might speculate that forma-
tion of advanced glycation end products is triggered by
factors in the dialysis procedures, i. e. glucose-contain-
ing fluids. This view is further substantiated by the
facts that
1) glycation of serum proteins, as revealed by fructos-
amine measurement, is increased in about 50% of non-
diabetic uraemics on dialysis and is related to advanced
glycation end products levels;
2) patients undergoing continuous ambulatory perito-
neal dialysis displayed essentially higher advanced gly-
cation end products levels than subjects on haemodialy-
sis;
3) elevation of advanced glycation end products in sub-
jects with end-stage renal disease on haemodialysis or
continuous ambulatory peritoneal dialysis is essentially
the same in the absence and in the presence of diabetes;
4) advanced glycation end products levels determined
before and after a dialysis session were found to be
increased after dialysis in about 50% of cases, as re-
ported previously (16);
5) advanced glycation end products levels declined after
kidney transplantation (13).
Further extensive work is necessary to examine the pos-
sible origin of serum advanced glycation end products
in subjects with end-stage renal disease.
In diabetics, we showed for the first time that serum
advanced glycation end products levels are related to
diabetic late complications, patients without sequelae
displaying values within the normal range, while in the
presence of complications mean advanced glycation end
products values are increased. An association between
serum advanced glycation end products and severity of
retinopathy but not of nephropathy was discernible. Var-
ying results were obtained when pentosidine (29, 30) or
fluorescence (31) were determined in human skin colla-
gen, showing correlations with retinopathy (31), ne-
phropathy (30) or both (29). Our present findings and
previous studies strongly indicate a link between ad-
vanced glycation end products and diabetic late compli-
cations in certain cases. However, it is still unknown
whether high serum advanced glycation end products
levels contribute to the pathogenesis of late complica-
tions or whether serum levels are increased due to de-
gradation products derived from highly glycated tissues.
Data from Vlassara et al. (32), however, indicate, that
serum advanced glycation end products might be patho-
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genie, as rat advanced glycation end products albumin
administered to normal rats induced glomerular sclerosis
and albuniinuria. As demonstrated here, about half of
the patients with late complications showed normal or
even decreased serum advanced glycation end products
levels. Unfortunately, in peripheral macroangiopathy
and polyneuropathy, a staging according to the severity
of complication was not possible. Further, it should be
mentioned that advanced glycation end products, if they
are really pathogenic, might be one component of a vari-
ety of factors leading to the development of diabetic late
complications.
The apparent increase in serum advanced glycation end
products in diabetics in relation to decreasing renal func-
tion (tab. 1) may be due to the presence of late complica-
tions. In the group of diabetics without renal failure, 15
patients suffered from late complications, while 19 out
of the 24 diabetics with moderate renal failure displayed
sequelae other than nephropathy, and six out of the eight
uraemic diabetics suffered from proliferative retinopa-
thy. Finally, one might assume that elevated advanced
glycation end products levels in patients on haemodialy-
sis or continuous ambulatory peritoneal dialysis are in-
volved in the development of complications of dialysis,
resembling diabetic late complications.
The observations in non-diabetic, non-uraemic patients
indicate that an increase in serum advanced glycation
end products is not confined to diabetics and patient with
renal disease, but also occurs in certain severely ill sub-
jects shortly before their death. Similar results were ob-
tained by Sell & Monnier (28) when measuring pentosi-
dine in skin collagen. The reason(s) for this phenomenon
is still unknown.
The nature of the immunologically reactive material is
not yet known. Epitopes may be bound to intact pro-
teins, peptides, amino acids or other still unknown com-
pounds. Further work is necessary to characterise and to
identify the immunologically reactive structures and to
examine their possible pathophysiological role in the de-
velopment of diabetic late complications.
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